glp 1 hepatic steatosis Role of glucagon-like peptide-1 receptor agonists in pediatric obesity and metabolic dysfunction associated steatotic liver disease Efficacy and safety of anti-obesity

Results may take time Some users did not notice changes with short-term use

Even with absorption enhancers, oral formulations achieve only 0.4-1% bioavailability compared to injectable versions

The present review provides (1) an overview in the pathophysiology of NAFLD, including the potential involvement of GLP-1 and glucagon, (2) an introduction to the currently available GLP-1RAs and (3) outlines the potential of emerging GLP-1RAs and GLP-1/glucagon receptor co-agonists in the treatment of NAFLD

doi: 10.7759/cureus.17887 22 LuJWangZCaoJChenYDongYA

Injectable glutathione is not FDA-approved for antioxidant, detox, or cosmetic/skin-lightening use, and there is no standardized or approved injectable dose presented for research and educational use only